Localization of benign Insulinomas using Glucagon-like Peptide-1 Receptor (GLP-1R) SPECT/CT and PET/CT in a prospective clinical study

Kwadwo Antwi¹, Melpomeni Fani¹, Tobias Heye¹, Guillaume Nicolas¹, Elmar Merkle¹, Jean Claude Reubi², Beat Gloor³, Emanuel Christ⁴, Damian Wild¹

* = shared last authors

¹Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Switzerland
²Division of Experimental Pathology, Department of Pathology, University of Bern, Switzerland
³Department of Visceral Surgery, University Hospital of Bern, Switzerland
⁴Division of Diabetology, Endocrinology, and Metabolism, Inselspital Bern, University Hospital and University of Bern, Switzerland

Background

• In patients with benign insulinomas conventional imaging is able to detect about 60-70% of the small pancreatic lesions (1-2 cm).
• Surgery is the only curative option for this disease.
• Preoperative localisation of the tumour is critical for the surgical strategy.
• Benign insulinoma express in nearly 100% GLP-1 receptors at a high density (ca. 5x higher than in normal beta-cells).
• GLP-1R single Photon Emission Computed Tomography (SPECT) has been shown to be a valid non-invasive tool for the localisation of benign insulinoma.
• A prospective randomized study comparing GLP-1R Positron Emission Tomography (PET)/CT and GLP-1R SPECT/CT has not yet been performed.

Methods

• Adult patients with with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled (ClinicalTrials.gov: NCT02127541).
• No signs of malignancy on conventional imaging.
• Investigations included ¹¹¹In-DOTA-exendin-4 SPECT/CT and ⁶⁸Ga-DOTA-exendin-4 PET/CT in a randomized order.
• Endpoint was correct detection rate (gold standard: histology).

Results

• Thirty-three patients (25 females, 8 males, age range 18-80 years, mean 49 years) were scanned until now.
• Previously performed cross-sectional imaging (CT/MRI) was negative or not conclusive in 25/33 (76%) of patients.
• 22 patients have been operated, two patients refused surgery and five patients are awaiting surgery.
• In this collective, the histopathological diagnosis of a benign insulinoma was confirmed in 19 patients, 1 patient had an adult islet cell hyperplasia. In 1 patient both intraoperative palpation and histological diagnosis did not confirm an insulinoma.
• In 1 patient symptoms of endogenous hypoglycemia ceased postoperative but histological diagnosis did not confirm the diagnosis. This patient was excluded from evaluation as the final diagnosis remained unclear.
• In 4 patients PET/CT, SPECT/CT as well as the previous performed conventional imaging did not find any suspicious lesion and were not operated up to date.

In this interim analysis:

• PET/CT (2.5h p.i.) showed an overall pooled sensitivity of 95%
• SPECT/CT (72h p.i.) showed an overall pooled sensitivity of 73%
• PET/CT was the only modality which correctly identified the area of islet cell hyperplasia (adult nesidioblastosis) within the pancreas.

Conclusion

1. Our interim analysis suggests that GLP-1R PET/CT performs better than GLP-1R SPECT/CT at a lower radiation dose and shorter examination time.
2. GLP-1R PET/CT will be a useful diagnostic tool in patients where cross sectional imaging (CT/MRI) fails to localize the insulinoma.

Figure 1: Transaxial ¹¹¹In-DOTA-exendin-4 SPECT/CT. The arrow shows focal uptake in the distal portion of the pancreatic tail.

Figure 2: Transaxial ⁶⁸Ga-DOTA-exendin-4 PET/CT. The arrow shows focal uptake in the distal portion of the pancreatic tail (same patient).

Figure 3: Results